Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
Cancer Discovery
|
May 17, 2020
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion-Driven NSCLC
Jiyeon Yun, Soo-Hwan Lee, Seok-Young Kim, et al.
Frontiers in Immunology
|
April 29, 2024
Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types
Dong Kwon Kim, Chai Young Lee, Yu Jin Han, et al.
EMBO Molecular Medicine
|
October 22, 2019
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
Mi Ran Yun, Hun Mi Choi, You Won Lee, et al.
BMC Cancer
|
April 16, 2020
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
Han Na Kang, Jae-Hwan Kim, A-Young Park, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 10, 2020
Dynamic changes in circulating PD-1<sup>+</sup>CD8<sup>+</sup> T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer
Chang Gon Kim, Min Hee Hong, Kyung Hwan Kim, et al.
Frontiers in Immunology
|
March 22, 2024
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production
Kwangmin Na, Seul Lee, Dong Kwon Kim, et al.
Cancer Research
|
April 20, 2018
Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors
Mi Ran Yun, Sun Min Lim, Seon-Kyu Kim, et al.
Cancer Research Communications
|
June 25, 2024
Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
Sun M Lim, Seong-San Kang, Dong K Kim, et al.
British Journal of Cancer
|
September 23, 2020
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Hye Ryun Kim, Han Na Kang, Mi Ran Yun, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 1, 2018
Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation
Han Na Kang, Jae Woo Choi, Hyo Sup Shim, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
Cancer Discovery
|
May 17, 2020
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion-Driven NSCLC
Jiyeon Yun, Soo-Hwan Lee, Seok-Young Kim, et al.
Frontiers in Immunology
|
April 29, 2024
Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types
Dong Kwon Kim, Chai Young Lee, Yu Jin Han, et al.
EMBO Molecular Medicine
|
October 22, 2019
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
Mi Ran Yun, Hun Mi Choi, You Won Lee, et al.
BMC Cancer
|
April 16, 2020
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
Han Na Kang, Jae-Hwan Kim, A-Young Park, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 10, 2020
Dynamic changes in circulating PD-1<sup>+</sup>CD8<sup>+</sup> T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer
Chang Gon Kim, Min Hee Hong, Kyung Hwan Kim, et al.
Frontiers in Immunology
|
March 22, 2024
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production
Kwangmin Na, Seul Lee, Dong Kwon Kim, et al.
Cancer Research
|
April 20, 2018
Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors
Mi Ran Yun, Sun Min Lim, Seon-Kyu Kim, et al.
Cancer Research Communications
|
June 25, 2024
Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
Sun M Lim, Seong-San Kang, Dong K Kim, et al.
British Journal of Cancer
|
September 23, 2020
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Hye Ryun Kim, Han Na Kang, Mi Ran Yun, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 1, 2018
Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation
Han Na Kang, Jae Woo Choi, Hyo Sup Shim, et al.
Page
of 6